- Home
- OC vs EXEL Comparison
OC vs EXEL Comparison
Compare OC & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OC
- EXEL
- Stock Information
- Founded
- OC 1938
- EXEL 1994
- Country
- OC United States
- EXEL United States
- Employees
- OC N/A
- EXEL N/A
- Industry
- OC Industrial Machinery/Components
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OC Industrials
- EXEL Health Care
- Exchange
- OC Nasdaq
- EXEL Nasdaq
- Market Cap
- OC 11.3B
- EXEL 12.0B
- IPO Year
- OC N/A
- EXEL 2000
- Fundamental
- Price
- OC $140.01
- EXEL $44.47
- Analyst Decision
- OC Buy
- EXEL Buy
- Analyst Count
- OC 11
- EXEL 18
- Target Price
- OC $187.40
- EXEL $44.24
- AVG Volume (30 Days)
- OC 748.8K
- EXEL 3.6M
- Earning Date
- OC 08-06-2025
- EXEL 07-28-2025
- Dividend Yield
- OC 1.97%
- EXEL N/A
- EPS Growth
- OC N/A
- EXEL 237.58
- EPS
- OC 2.92
- EXEL 2.20
- Revenue
- OC $11,488,000,000.00
- EXEL $2,298,922,000.00
- Revenue This Year
- OC N/A
- EXEL $9.93
- Revenue Next Year
- OC $2.02
- EXEL $13.17
- P/E Ratio
- OC $48.05
- EXEL $20.18
- Revenue Growth
- OC 22.70
- EXEL 24.49
- 52 Week Low
- OC $123.41
- EXEL $22.20
- 52 Week High
- OC $214.53
- EXEL $49.62
- Technical
- Relative Strength Index (RSI)
- OC 48.22
- EXEL 53.42
- Support Level
- OC $138.52
- EXEL $44.03
- Resistance Level
- OC $143.04
- EXEL $45.52
- Average True Range (ATR)
- OC 4.10
- EXEL 1.44
- MACD
- OC -0.44
- EXEL -0.06
- Stochastic Oscillator
- OC 24.61
- EXEL 22.78
About OC Owens Corning Inc New
Owens-Corning Inc is a manufacturer of glass fiber utilized in composites and building materials. It has an integrated business model with four reportable segments: Composites, Insulation, Doors, and Roofing. It generates maximum revenue from the Roofing segment. Its Roofing segment laminate and strip asphalt roofing shingles, roofing components, synthetic packaging materials, and oxidized asphalt. It meets the growing demand for longer-lasting, aesthetically attractive laminate products with modest capital investment. Geographically the company generates the majority of its revenue from the United States.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.